Redeye is encouraged by FluoGuide receiving FDA Fast Track Designation for FG001 in High-Grade Glioma. This gives positive regulatory momentum ahead of the U.S. Phase 2 registration trial. We expect the share to trade up at least 15% today.
LÄS MER
